Nimodipin Altan (Nimodipine)

Nimodipine blocks L‑type calcium channels in the smooth muscle of cerebral arteries. This inhibition reduces calcium‑mediated contraction, causing selective vasodilation of brain vessels and enhancing cerebral perfusion, which is critical after a subarachnoid bleed.

The dosing regimen for Nimodipin Altan is determined by the treating physician based on the patient’s clinical status, weight, and renal/hepatic function. The prescriber selects the appropriate infusion rate and duration according to established clinical guidelines.

Safety data for nimodipine in pregnancy and lactation are limited. It should be used only when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the prescribing clinician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Nimodipine has a higher affinity for cerebral vessels compared with many systemic calcium channel blockers such as nicardipine or verapamil. This selectivity provides more pronounced cerebral vasodilation while producing relatively less peripheral hypotension, making it the preferred agent for subarachnoid‑hemorrhage‑related vasospasm.

Nimodipin Altan must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Do not use the product if it has been exposed to temperatures outside the recommended range.

The product is administered intravenously under aseptic conditions. It is typically given as a continuous infusion or intermittent IV injection, as directed by the prescriber, using sterile equipment and following standard infusion protocols.

The most serious adverse events include severe hypotension, myocardial infarction, and hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome. Prompt recognition and management of these events are essential during therapy.

Patients with known hypersensitivity to nimodipine or any component of the formulation, those with severe uncontrolled hypotension, or individuals in whom the risk of cerebral vasospasm is not present should not receive the drug. Contra‑indications are determined by the treating physician.